Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs SODIUM PHENYLACETATE AND SODIUM BENZOATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with urea cycle disorders (UCDs) involving deficiencies of carbamyl phosphate synthetase (CPS), ornithine transcarbamoylase (OTC), argininosuccinic acid synthetase (AS), argininosuccinic acid lyase (AL), or arginase (ARG). Also used for maintenance therapy in chronic management of UCDs.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
The terminal elimination half-life of phenylacetate is approximately 0.5-0.8 hours; however, its active conjugate phenylacetylglutamine has a half-life of about 1.2-1.5 hours. For benzoate, the half-life is approximately 0.5-1 hour. In the context of hyperammonemia treatment, the clinical effect correlates with the rapid formation of conjugates, and the half-life reflects quick clearance. In neonates or patients with renal impairment, half-life may be prolonged.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Sodium phenylacetate is metabolized via conjugation with glutamine to form phenylacetylglutamine. Sodium benzoate is metabolized via conjugation with glycine to form hippurate. Both metabolites are rapidly excreted by the kidneys.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Sodium phenylacetate and sodium benzoate are primarily excreted renally. Phenylacetate is conjugated with glutamine to form phenylacetylglutamine, which is rapidly eliminated in urine. Benzoate is conjugated with glycine to form hippurate, also renally eliminated. Approximately 80-100% of the administered dose is recovered in urine as conjugates and minor metabolites. Fecal excretion is negligible (<5%).
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Phenylacetate and benzoate are highly protein bound, primarily to albumin. Protein binding is approximately 80-90% for phenylacetate and 75-85% for benzoate. Binding may be saturable at high concentrations.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
The apparent volume of distribution for both drugs is small, approximately 0.2-0.3 L/kg, indicating limited extravascular distribution. This is consistent with their high protein binding and confinement to the vascular and interstitial spaces.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Oral bioavailability is high, approximately 80-90% for both components, as they are well absorbed. However, for acute hyperammonemia, intravenous administration is preferred to ensure rapid and complete delivery.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-50: reduce dose by 50% and monitor ammonia levels.
No dosage adjustment required for hepatic impairment.
No specific adjustment; use with caution in severe hepatic impairment due to potential for increased ammonia.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Same weight-based dosing as adults: 5.5 g/m² IV loading then 5.5 g/m²/24h continuous infusion.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
No specific adjustment; monitor renal function and consider reduced dosing based on creatinine clearance.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
WARNING: Contains sodium (approximately 30.2 mg/m L from sodium phenylacetate and sodium benzoate). Use caution in patients with congestive heart failure, severe renal insufficiency, or conditions with sodium retention. Additionally, neurotoxicity has been associated with phenylacetate accumulation; monitor plasma levels.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Monitor ammonia levels, electrolytes, and neurological status. Risk of hypernatremia due to sodium content. Phenylacetate may cause neurotoxicity (tremors, agitation, coma) at high concentrations. Use with caution in patients with hepatic or renal impairment. Not recommended for patients with known hypersensitivity to phenylacetate or benzoate. Extravasation risk: avoid extravasation; if occurs, treat locally.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Known hypersensitivity to sodium phenylacetate, sodium benzoate, or any component of the formulation; pre-existing severe hypernatremia (serum sodium >150 m Eq/L); neonates with hyperbilirubinemia (risk of kernicterus due to benzoate displacing bilirubin from albumin).
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Administer with food or enteral feeding to reduce gastrointestinal irritation. Avoid high-protein meals during treatment as they may increase ammonia production. No specific food-drug interactions; restrict dietary protein as part of urea cycle disorder management (typically 0.5-2 g/kg/day).
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
FDA Pregnancy Category C. Animal studies with sodium phenylacetate and sodium benzoate at doses equivalent to human therapeutic exposure have shown teratogenic effects (skeletal and visceral malformations) when administered during organogenesis. Human data are insufficient to determine fetal risk. In the first trimester, potential for teratogenicity exists; use only if maternal benefit outweighs risk. Second and third trimester exposure may be associated with neonatal metabolic alkalosis, hypernatremia, and potential for kernicterus due to displacement of bilirubin from albumin. Avoid use during labor and delivery due to risk of neonatal hyperbilirubinemia.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Excretion into human breast milk is unknown. The molecular weight of both sodium phenylacetate and sodium benzoate suggests potential for transfer into breast milk. The Milk-to-Plasma ratio is not established. Because of potential for serious adverse reactions in nursing infants (e.g., metabolic acidosis, neurotoxicity), breastfeeding is not recommended during therapy. Alternative feeding methods should be considered.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Pregnancy-induced hemodilution and increased renal clearance may require dose adjustments to maintain therapeutic ammonia levels. Monitor serum ammonia closely; consider starting at lower doses and titrating based on response. Due to increased plasma volume, distribution volume changes, and enhanced renal excretion, dose adjustments upward may be necessary. However, avoid excessive dosing to prevent maternal metabolic alkalosis or hypernatremia. Individualize therapy based on frequent ammonia monitoring, with consideration of gestational age. Postpartum, dose may need to be reduced as renal function normalizes.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Administer intravenously via central line due to hypertonicity (p H 9-9.5). Monitor serum ammonia, potassium, and bicarbonate closely; hypokalemia and metabolic alkalosis are common. Use with caution in renal impairment (dose adjust for GFR <30 m L/min). Discontinue if hypernatremia or volume overload occurs. Caloric content: 2.5 kcal/m L from phenylacetate and benzoate.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
This medication is used to remove excess ammonia from your blood due to a urea cycle disorder.,It is given through a central intravenous line; report any pain, redness, or swelling at the infusion site.,You may experience nausea, vomiting, or headache; notify your healthcare provider if severe.,Regular blood tests are necessary to monitor your ammonia levels and electrolytes.,Avoid taking other medications without consulting your doctor, as they may affect ammonia levels.
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs SODIUM PHENYLACETATE AND SODIUM BENZOATE, answered by our medical review team.
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. SODIUM PHENYLACETATE AND SODIUM BENZOATE is a Ammonia Detoxicant that works by Sodium phenylacetate and sodium benzoate provide an alternative pathway for nitrogen excretion in patients with urea cycle disorders. Phenylacetate conjugates with glutamine to form phenylacetylglutamine, which is renally excreted, thereby eliminating waste nitrogen. Benzoate conjugates with glycine to form hippurate, which is also excreted in urine, removing ammonia precursors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and SODIUM PHENYLACETATE AND SODIUM BENZOATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. The standard adult dose of SODIUM PHENYLACETATE AND SODIUM BENZOATE is: Intravenous: Loading dose of 5.5 g/m² over 90-120 minutes, then continuous infusion of 5.5 g/m² over 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and SODIUM PHENYLACETATE AND SODIUM BENZOATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . SODIUM PHENYLACETATE AND SODIUM BENZOATE is classified as Category C. FDA Pregnancy Category C. Animal studies with sodium phenylacetate and sodium benzoate at doses equivalent to human therapeutic exposure have shown teratogenic effects (skeletal an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.